Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design.

Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Abstract Text:

Buyong Ma,Ruth Nussinov,

Protein-protein interactions are crucial to biological functions. Consequently, designing drugs to control protein-protein interactions is receiving increasing attention. Protein structures can associate in different ways. Analysis of the structures of protein-protein complexes using amino acid sequence order-independent multiple structural comparison algorithms, led us to conclude that the amino acids Trp, Met, and Phe are important for protein-protein interactions. Hence, in principle, drug design targeting the Trp/Met/Phe should modulate protein functions effectively. Several clusters of the Trp/Met/Phe residues are involved in the p53 protein-protein interactions. The best example in this regard is the Phe19/Trp23 of p53, which binds to transcriptional factors and to the MDM2 protein. In the HIV related proteins, the Trp/Met/Phe residues have roles in the dimerization of the transcriptase (p51/p66) and in cell-fusion processes, including the gp120-CD4 interaction and the gp41 six-helix bundle formation. Trp/Met/Phe residues are preferred in 'normal' functional protein-protein interactions and they also appear to be exploited in amyloid formation, especially the phenylalanine. Comparison of binding propensity and amyloid formation preference reveals that apart from Lysine, Isoleucine is the least structurally conserved in protein binding sites and has a high propensity in sequences forming amyloids. Thus, this may suggest that nature tends to avoid Ile conservation in protein-protein interaction to avoid amyloid formation. In this regards, Trp/Met/Phe as well as Ile may be targeted to modulate protein-protein interaction.

Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Publishing Authors By Initials

B Ma,R Nussinov,

For similar proteins: dna-binding proteins: tumor suppressor protein p53 research abstracts see: proteins: dna-binding proteins: tumor suppressor protein p53 research

PUBMED ID PMID:

MEDLINE DATE:

Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Journal Published:

PUBLICATION TYPE: Review

Journal: Current topics in medicinal chemistry

VOLUME: 7

Page Numbers: 999-1005

Journal Abbreviation:

ISSN: 1873-4294

DAY: 3

MONTH: 12

YEAR: 2007

Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Information

Number of References: 44

LANGUAGE: eng

NlmUniqueID: 101119673

Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Keywords Mesh Terms:

KEYWORDS: Tumor Suppressor Protein p53

MESH TERMS: chemistry

Chemical & Substance for Abstract: Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Information

Substance Name: Tryptophan

Registry Number: 73-22-3

Grant and Affiliation Information for Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design.

AFFILIATION: Basic Research Program, SAIC-Frederick, Inc., Center for Cancer Research Nanobiology Program, NCI-Frederick, Frederick, MD 21702, USA. mab@ncifcrf.gov

Country: Netherlands

AGENCY: United States NCI

GRANT: N01-CO-12400

ACRONYM: CO

MEDLINETA: Curr Top Med Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design Related Publications

• "Similarity trap" in protein-protein interactions could be carcinogenic: simulations of p53 core domain complexed with 53BP1 and BRCA1 BRCT domains.
• A hierarchical protein folding scheme based on the building block folding model.
• Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
• Allostery: Absence of a Change in Shape Does Not Imply that Allostery Is Not at Play.
• Backbone conformational preferences and pseudorotational ring puckering of 1-aminocyclopentane-1-carboxylic acid.
• Changing the charge distribution of beta-helical-based nanostructures can provide the conditions for charge transfer.
• Conformational study of the protegrin-1 (PG-1) dimer interaction with lipid bilayers and its effect.
• Consensus features in amyloid fibrils: sheet-sheet recognition via a (polar or nonpolar) zipper structure.
• Designing a nanotube using naturally occurring protein building blocks.
• How different are structurally flexible and rigid binding sites? Sequence and structural features discriminating proteins that do and do not undergo conformational change upon ligand binding.
• Interaction of protegrin-1 with lipid bilayers: membrane thinning effect.
• Modeling the Alzheimer Abeta17-42 fibril architecture: tight intermolecular sheet-sheet association and intramolecular hydrated cavities.
• Models of beta-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process.
• Modular architecture of protein structures and allosteric communications: potential implications for signaling proteins and regulatory linkages.
• MolAxis: a server for identification of channels in macromolecules.
• Molecular dynamics simulations of Alzheimer Abeta40 elongation and lateral association.
• Nanostructure design using protein building blocks enhanced by conformationally constrained synthetic residues.
• New structures help the modeling of toxic amyloidss ion channels.
• Principles of nanostructure design with protein building blocks.
• Residue centrality, functionally important residues, and active site shape: analysis of enzyme and non-enzyme families.
• Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets.
• Similar binding sites and different partners: implications to shared proteins in cellular pathways.
• Simulations as analytical tools to understand protein aggregation and predict amyloid conformation.
• Structural basis for p53 binding-induced DNA bending.
• Structural dynamics of the cooperative binding of organic molecules in the human cytochrome P450 3A4.
• Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35.
• Structure by design: from single proteins and their building blocks to nanostructures.
• Towards drugs targeting multiple proteins in a systems biology approach.
• Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design.
• p53-Induced DNA bending: the interplay between p53-DNA and p53-p53 interactions.